Circular Genomics MindLight

Circular Genomics has launched a blood-based PCR assay for the detection of circular RNA biomarkers to help predict whether a patient with major depressive disorder will respond to selective serotonin reuptake inhibitor (SSRI) antidepressant therapy. The MindLight assay is used to aid the management of patients who have a diagnosis of depression. Circular Genomics said that the test has a prognostic accuracy of 77 percent, and patients with test results that suggest a high likelihood of response are 3.4 times more likely to respond to SSRIs than those whose results suggest a low likelihood of response.